Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · IEX Real-Time Price · USD
2.940
+0.090 (3.16%)
At close: Apr 26, 2024, 4:00 PM
2.970
+0.030 (1.02%)
After-hours: Apr 26, 2024, 7:31 PM EDT
Mersana Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for MRSN stock have an average target of 5.57, with a low estimate of 1.00 and a high estimate of 9.00. The average target predicts an increase of 89.46% from the current stock price of 2.94.
Analyst Consensus: Buy
* Price targets were last updated on Mar 19, 2024.
Analyst Ratings
The average analyst rating for MRSN stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 3 | 3 | 3 |
| Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell → Hold Upgrades $5 | Sell → Hold | Upgrades | $5 | +70.07% | Mar 19, 2024 |
| Wedbush | Wedbush | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +138.10% | Feb 29, 2024 |
| Truist Securities | Truist Securities | Hold → Strong Buy Upgrades $9 | Hold → Strong Buy | Upgrades | $9 | +206.12% | Feb 29, 2024 |
| Baird | Baird | Hold Maintains $1 → $5 | Hold | Maintains | $1 → $5 | +70.07% | Feb 29, 2024 |
| Guggenheim | Guggenheim | Hold → Strong Buy Upgrades $7 | Hold → Strong Buy | Upgrades | $7 | +138.10% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
38.44M
from 36.86M
Increased by 4.30%
Revenue Next Year
29.97M
from 38.44M
Decreased by -22.03%
EPS This Year
-0.68
from -1.48
EPS Next Year
-0.74
from -0.68
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 73.5M | 45.3M | 44.8M | 44.9M | 123.2M |
| Avg | 38.4M | 30.0M | 19.6M | 29.3M | 63.6M |
| Low | n/a | n/a | n/a | 18.0M | 24.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 99.4% | 17.7% | 49.6% | 128.7% | 320.9% |
| Avg | 4.3% | -22.0% | -34.5% | 49.2% | 117.5% |
| Low | - | - | - | -8.3% | -16.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.26 | -0.35 | -0.27 | -0.38 | -1.19 |
| Avg | -0.68 | -0.74 | -0.72 | -0.70 | -1.15 |
| Low | -0.85 | -0.89 | -1.03 | -1.00 | -1.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.